Curiosity Cube Teaches More Than 43,000 Students About Sustainability
Celebrating its sixth annual tour, the Curiosity Cube from MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, traveled across North America and Europe during 2024 to fuel curiosity and discovery among visitors.
The 2024 tour brought a new look, to the Curiosity Cube's exterior and new lessons focused on sustainability. With a new look and lessons, the goal of the Curiosity Cube remained the same: enhance access to science education and foster innovation in the next generation of scientists. Through 282 events, more than 43,000 students in 208 communities across 14 countries learned how they can impact the planet by making sustainable choices through hands-on experiments led by real-life scientists at MilliporeSigma.
What does the Curiosity Cube have in store for 2025? Stay tuned for exciting news to come!
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
EMD Serono Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the primary endpoint of BICLA dose-response relationship at Week 24 was not met Data show encouraging efficacy in a large subgroup of SLE patients with active cutaneous manifestations at baseline, including improved response rates in key disease activity measurements There is a substantial unmet treatment need for the estimated 70-80% of SLE patients who experience active cutaneous manifestations, which can profoundly impact quality of life1 BOSTON, June 12, 2025--(BUSINESS WIRE)--Not intended for media outside the U.S. or Canada EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an investigational, oral, novel TLR7/8 inhibitor in systemic lupus erythematosus (SLE). Although it did not meet the primary endpoint of dose-response relationship, when compared to placebo, enpatoran demonstrated improvements in measures of both systemic and cutaneous disease activity in prespecified SLE subpopulations despite standard of care (SoC), including those with active cutaneous manifestations at baseline [(CLASI-A) ≥8], and was overall well tolerated. These findings will be presented in a late-breaking oral presentation at the 2025 European Congress of Rheumatology (EULAR) in Barcelona (Abstract # LB0004). "Analyses of Cohort B contribute to our understanding of enpatoran's potential to address the critical unmet needs for patients living with lupus, including those experiencing significant skin manifestations. These manifestations are often part of the systemic activity or flare, which can be painful and have a considerable impact on quality of life," said principal investigator Prof. Eric Morand, from Monash University and Monash Health. "The improvements observed in key disease measures represent a meaningful advancement in our ongoing investigation of the TLR7/8 inhibition approach for patients insufficiently managed by current therapies." WILLOW is a global, multicenter, randomized, placebo-controlled Phase 2 study evaluating three doses of oral enpatoran taken twice daily (25 mg, 50 mg and 100 mg) versus placebo plus SoC over 24 weeks. The study features a unique design across two lupus cohorts, including both patients with active SLE and cutaneous lupus erythematosus (CLE). Cohort B of the study was designed to evaluate the dose-response relationship of enpatoran in reducing disease activity, based on the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response rate at Week 24 and enrolled SLE patients who had moderate or severe active disease despite SoC. Cohort B showed positive results in secondary and exploratory endpoints and within prespecified patient subpopulations. In patients with active skin disease (CLASI-A ≥8), BICLA response rates were up to 58.6% while placebo response rates were 31.7%, and up to 60.5% of patients receiving enpatoran showed a CLASI-70 response, compared with 26.8% for placebo, at Week 24. In addition, the subgroups of patients with high corticosteroid (prednisone-equivalent ≥10 mg/day) use and those with high interferon gene signature (IFN-GS) at baseline also showed higher and relevant BICLA response rates for enpatoran compared to placebo. As presented earlier this year at LUPUS 2025, Cohort A analyses from the WILLOW study showed clinically meaningful improvement in disease activity in patients with CLE and mild SLE with active lupus rash at Weeks 16 and 24. Overall, for skin-related signs and symptoms, comparable improvements were observed in Cohort B relative to Cohort A, reinforcing the potential efficacy of enpatoran in patients with cutaneous manifestations of lupus erythematosus with or without systemic disease. "The efficacy and tolerability results from Cohort B, particularly among those with active skin involvement—a manifestation that affects most lupus patients—are consistent with our observations from Cohort A. The lupus rash is not only a visible symptom but is also closely linked to the underlying systemic activity of lupus," said Jan Klatt, Head of Development Unit Neurology & Immunology for the Healthcare business of Merck KGaA, Darmstadt, Germany. "We are set to initiate regulatory discussions with key health authorities to determine the most effective pathway for bringing enpatoran to patients." Enpatoran was well-tolerated and exhibited a manageable safety profile consistent with previous studies, with no new safety signals identified. Rates of treatment-emergent adverse events (TEAEs) were comparable between all enpatoran arms and placebo, ranging from 60.6% to 64.2%, and the most frequently reported TEAEs were infections and infestations. These results further support the anticipated favorable safety profile of enpatoran. About Enpatoran Enpatoran is a selective Toll-like receptor (TLR)7/8 inhibitor under investigation for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). By inhibiting TLR7/8 activation, enpatoran may help reduce pro-inflammatory cytokines and autoantibody production, potentially addressing underlying mechanisms of chronic inflammation and disease progression in lupus. With its novel proposed mechanism of action and oral administration, enpatoran has the potential to be a first-in-class treatment for patients across lupus conditions. Enpatoran is currently under clinical investigation and is not approved for any use anywhere in the world. About the Phase 2 WILLOW Clinical Study WILLOW (NCT05162586) is a randomized, double-blind, placebo-controlled Phase 2 proof of concept and dose-finding study designed to evaluate the efficacy and safety of enpatoran in patients with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). The study incorporates a basket design, including two cohorts – Cohort A including patients with CLE or SLE with active lupus rash and Cohort B including patients with active SLE. The WILLOW study aims to advance the understanding of enpatoran's therapeutic potential and to help address significant unmet needs in lupus treatment. About Lupus Erythematosus Lupus erythematosus is a chronic autoimmune disease that can affect various parts of the body, including the skin, joints, kidneys and other organs. It occurs when the immune system mistakenly attacks healthy tissues, leading to inflammation, pain and potential organ damage. There are multiple types of lupus, with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) being two primary forms. Symptoms can range from mild to life-threatening, often including fatigue, joint pain, rashes and organ involvement. Lupus disproportionately impacts women and people of color, and despite available treatments, many patients experience unmet needs due to limited efficacy or side effects. EMD Serono in Neurology and Immunology EMD Serono has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company's current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine) tablets. EMD Serono aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to EMD Serono's commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and generalized myasthenia gravis (gMG). About EMD Serono, Inc. EMD Serono - the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada - aspires to create, improve and prolong life for people living with difficult-to-treat conditions like infertility, multiple sclerosis and cancer. The business is imagining the future of healthcare by working to translate the discovery of molecules into potentially meaningful outcomes for people with serious unmet medical needs. EMD Serono's global roots go back more than 350 years with Merck KGaA, Darmstadt, Germany. Today, the business has approximately 1,050 employees around the country with commercial, clinical and research operations in Massachusetts. About Merck KGaA, Darmstadt, Germany Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. 1 Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011 Oct;6(4):330-6. PMID: 22879850; PMCID: PMC3391953. View source version on Contacts Media Relations Phone: +1 781 427 1892 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-06-2025
- Yahoo
CRISPR Market Research and Competitive Landscape Report 2025 - Global Forecast to 2030: Rising Adoption in Research and Therapy Drives Growth with Thermo Fisher Scientific and Merck Leading
Growth is fueled by increased adoption in research and industry, advancements in CRISPR tools, and rising investments in biotechnology. Key applications include drug discovery and gene therapy, with pharmaceutical and biotech companies dominating the market. North America leads the sector, driven by innovative research and strong investment. Amidst this expansion, companies like Thermo Fisher Scientific and Merck KGaA emerge as market leaders, shaping the competitive landscape with new developments and collaborations. CRISPR Market Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "CRISPR Market by Offering [Product (Kits, Enzymes, Libraries), Service (gRNA Synthesis, Cell Line Development, Screening, Validation)], Application (Drug Discovery, Development, Agriculture) Competitive Landscape, Company Profiles -Global Forecast to 2030" has been added to offering. The global CRISPR market is set to expand from USD 3.21 billion in 2025 to USD 5.47 billion by 2030, registering a robust CAGR of 11.2% The report presents an analysis of market drivers, focusing on the rising demand for CRISPR-based therapies and ongoing technological advancements. It identifies key opportunities for CRISPR in areas such as vaccines and genetic disease treatments. A comprehensive evaluation of market shares and growth strategies of leading companies is included, along with an overview of challenges, particularly regulatory hurdles, that affect market progression. Growth is fueled by the technology's expanding use in research, clinical, and industrial applications, supported by increased investments in biotechnology R&D and the growing prevalence of genetic disorders. As CRISPR tools and delivery systems improve, and regulatory frameworks become more supportive, the integration of CRISPR into research and therapeutic pipelines accelerates. Leading companies include Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, GenScript, Takara Bio, Creative Biogene, Fujian SunyBiotech, Caribou Biosciences, Lonza Group, Danaher Corporation, among others. Products Dominated the Market in 2024 The CRISPR market is divided into products and services. The products segment, which includes CRISPR kits & enzymes and CRISPR libraries, leads the market. These products are essential in academic, clinical, and industrial research for genome editing and therapeutic development. This segment's growth is driven by the demand for standardized and innovative CRISPR products. Drug Discovery & Development: A Fast-Growing Application Segment Within applications, drug discovery & development is the largest and fastest-growing segment, leveraging CRISPR to find gene-disease links and streamline drug functions. This reduces timelines and increases success probabilities. Pharmaceutical and biotechnology firms are pivotal in incorporating CRISPR for personalized medicine and functional genomics, further driving the technology's adoption. Pharmaceutical & Biotechnology Companies' Market Dominance in 2024 These companies led the CRISPR products market in 2024, thanks to increased investment in cell and gene therapies, and the need for precise genetic tools. Their financial strength allows them to implement advanced CRISPR technologies effectively, bolstering their market position. North America's Leadership in the CRISPR Market North America, with its prominent research institutions and substantial biotech investments, captured the largest CRISPR market share in 2024. The region's emphasis on medical research and personalized medicine offers it a competitive edge. European markets, especially in Germany, the UK, and France, are also seeing robust growth due to heightened R&D activity. Key Attributes: Report Attribute Details No. of Pages 267 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $3.21 Billion Forecasted Market Value (USD) by 2030 $5.47 Billion Compound Annual Growth Rate 11.2% Regions Covered Global Market Dynamics Drivers Growing Demand for Crispr-Based Gene Therapies Advancements in Crispr Technology Growing Government and Private Investments and Funding for Crispr Technology Restraints Technical Challenges Associated With Crispr Technology Opportunities Development of New Vaccines and Treatments for Genetic Diseases Expanding Industrial and Agricultural Applications of Crispr Challenges Regulatory Hurdles for Crispr Advancements Technology Analysis Key Technologies Crispr-Cas Systems Grna Design & Optimization High-Throughput Crispr Screening Complementary Technologies Synthetic Biology Single-Cell Genomics Next-Generation Sequencing Adjacent Technologies Stem Cell Engineering Synthetic Dna & Gene Synthesis Microfluidics Company Profiles Thermo Fisher Scientific Inc. Merck Kgaa Agilent Technologies, Inc. Genscript Revvity Lonza Danaher Corporation Takara Bio Inc. Creative Biogene Fujian Sunybiotech Co., Ltd. Editco Caribou Biosciences, Inc. Hera Biolabs Origene Technologies, Inc. Cellecta, Inc. Mammoth Biosciences, Inc. Applied Stemcell New England Biolabs Toolgen, Inc. Genecopoeia, Inc. Twist Bioscience Synthego Egenesis Inscripta, Inc. Precision Biosciences For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment CRISPR Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-06-2025
- Yahoo
CRISPR Market Research and Competitive Landscape Report 2025 - Global Forecast to 2030: Rising Adoption in Research and Therapy Drives Growth with Thermo Fisher Scientific and Merck Leading
Growth is fueled by increased adoption in research and industry, advancements in CRISPR tools, and rising investments in biotechnology. Key applications include drug discovery and gene therapy, with pharmaceutical and biotech companies dominating the market. North America leads the sector, driven by innovative research and strong investment. Amidst this expansion, companies like Thermo Fisher Scientific and Merck KGaA emerge as market leaders, shaping the competitive landscape with new developments and collaborations. CRISPR Market Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "CRISPR Market by Offering [Product (Kits, Enzymes, Libraries), Service (gRNA Synthesis, Cell Line Development, Screening, Validation)], Application (Drug Discovery, Development, Agriculture) Competitive Landscape, Company Profiles -Global Forecast to 2030" has been added to offering. The global CRISPR market is set to expand from USD 3.21 billion in 2025 to USD 5.47 billion by 2030, registering a robust CAGR of 11.2% The report presents an analysis of market drivers, focusing on the rising demand for CRISPR-based therapies and ongoing technological advancements. It identifies key opportunities for CRISPR in areas such as vaccines and genetic disease treatments. A comprehensive evaluation of market shares and growth strategies of leading companies is included, along with an overview of challenges, particularly regulatory hurdles, that affect market progression. Growth is fueled by the technology's expanding use in research, clinical, and industrial applications, supported by increased investments in biotechnology R&D and the growing prevalence of genetic disorders. As CRISPR tools and delivery systems improve, and regulatory frameworks become more supportive, the integration of CRISPR into research and therapeutic pipelines accelerates. Leading companies include Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, GenScript, Takara Bio, Creative Biogene, Fujian SunyBiotech, Caribou Biosciences, Lonza Group, Danaher Corporation, among others. Products Dominated the Market in 2024 The CRISPR market is divided into products and services. The products segment, which includes CRISPR kits & enzymes and CRISPR libraries, leads the market. These products are essential in academic, clinical, and industrial research for genome editing and therapeutic development. This segment's growth is driven by the demand for standardized and innovative CRISPR products. Drug Discovery & Development: A Fast-Growing Application Segment Within applications, drug discovery & development is the largest and fastest-growing segment, leveraging CRISPR to find gene-disease links and streamline drug functions. This reduces timelines and increases success probabilities. Pharmaceutical and biotechnology firms are pivotal in incorporating CRISPR for personalized medicine and functional genomics, further driving the technology's adoption. Pharmaceutical & Biotechnology Companies' Market Dominance in 2024 These companies led the CRISPR products market in 2024, thanks to increased investment in cell and gene therapies, and the need for precise genetic tools. Their financial strength allows them to implement advanced CRISPR technologies effectively, bolstering their market position. North America's Leadership in the CRISPR Market North America, with its prominent research institutions and substantial biotech investments, captured the largest CRISPR market share in 2024. The region's emphasis on medical research and personalized medicine offers it a competitive edge. European markets, especially in Germany, the UK, and France, are also seeing robust growth due to heightened R&D activity. Key Attributes: Report Attribute Details No. of Pages 267 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $3.21 Billion Forecasted Market Value (USD) by 2030 $5.47 Billion Compound Annual Growth Rate 11.2% Regions Covered Global Market Dynamics Drivers Growing Demand for Crispr-Based Gene Therapies Advancements in Crispr Technology Growing Government and Private Investments and Funding for Crispr Technology Restraints Technical Challenges Associated With Crispr Technology Opportunities Development of New Vaccines and Treatments for Genetic Diseases Expanding Industrial and Agricultural Applications of Crispr Challenges Regulatory Hurdles for Crispr Advancements Technology Analysis Key Technologies Crispr-Cas Systems Grna Design & Optimization High-Throughput Crispr Screening Complementary Technologies Synthetic Biology Single-Cell Genomics Next-Generation Sequencing Adjacent Technologies Stem Cell Engineering Synthetic Dna & Gene Synthesis Microfluidics Company Profiles Thermo Fisher Scientific Inc. Merck Kgaa Agilent Technologies, Inc. Genscript Revvity Lonza Danaher Corporation Takara Bio Inc. Creative Biogene Fujian Sunybiotech Co., Ltd. Editco Caribou Biosciences, Inc. Hera Biolabs Origene Technologies, Inc. Cellecta, Inc. Mammoth Biosciences, Inc. Applied Stemcell New England Biolabs Toolgen, Inc. Genecopoeia, Inc. Twist Bioscience Synthego Egenesis Inscripta, Inc. Precision Biosciences For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment CRISPR Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
